Contribution of L-Tyrosine to Human Decision Making in Stressful Situations
- Conditions
- Stress, Psychological
- Interventions
- Biological: Blood collectionDrug: PlaceboBehavioral: Cognitive tasksBehavioral: Anxiety scaleOther: Stress exposureDevice: Electromyography (EMG)Device: Electroencephalography (EEG)
- Registration Number
- NCT04518254
- Lead Sponsor
- Direction Centrale du Service de Santé des Armées
- Brief Summary
L-tyrosine is a chemical precursor of dopamine. Under specific conditions, tyrosine administration can increase brain dopamine levels and therefore several studies have explored whether tyrosine supplementation can have a beneficial effect on cognitive and behavioural performance that is dependent on dopaminergic function. However, the effects of tyrosine supplementation are mixed: some studies show positive effects while others do not. Stress leads to an increase in dopaminergic activity and turnover in the brain, resulting in a decrease in brain dopamine levels. We propose to study the contribution of tyrosine to decision making and more particularly to the processes of response selection (mediated by the prefrontal cortex and under the influence of the dopaminergic system) in stressful situations.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 17
- From 18 to 65 years of age
- Tyrosine intake within the previous 15 days
- History of neurological or psychiatric disorder
- History of nephrological or endocrine disorder or liver failure
- Hereditary tyrosinemia
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description Tyrosine - Test Blood collection 4 similar visits (day 0, day 3, day 6, day 9): Administration of L-tyrosine No stress exposure Tyrosine - Stress L-Tyrosine 500 Mg 4 similar visits (day 0, day 3, day 6, day 9): Administration of L-tyrosine Stress exposure Tyrosine - Test L-Tyrosine 500 Mg 4 similar visits (day 0, day 3, day 6, day 9): Administration of L-tyrosine No stress exposure Tyrosine - Test Cognitive tasks 4 similar visits (day 0, day 3, day 6, day 9): Administration of L-tyrosine No stress exposure Tyrosine - Test Anxiety scale 4 similar visits (day 0, day 3, day 6, day 9): Administration of L-tyrosine No stress exposure Tyrosine - Test Electromyography (EMG) 4 similar visits (day 0, day 3, day 6, day 9): Administration of L-tyrosine No stress exposure Tyrosine - Test Electroencephalography (EEG) 4 similar visits (day 0, day 3, day 6, day 9): Administration of L-tyrosine No stress exposure Tyrosine - Stress Blood collection 4 similar visits (day 0, day 3, day 6, day 9): Administration of L-tyrosine Stress exposure Tyrosine - Stress Cognitive tasks 4 similar visits (day 0, day 3, day 6, day 9): Administration of L-tyrosine Stress exposure Tyrosine - Stress Stress exposure 4 similar visits (day 0, day 3, day 6, day 9): Administration of L-tyrosine Stress exposure Tyrosine - Stress Anxiety scale 4 similar visits (day 0, day 3, day 6, day 9): Administration of L-tyrosine Stress exposure Tyrosine - Stress Electromyography (EMG) 4 similar visits (day 0, day 3, day 6, day 9): Administration of L-tyrosine Stress exposure Tyrosine - Stress Electroencephalography (EEG) 4 similar visits (day 0, day 3, day 6, day 9): Administration of L-tyrosine Stress exposure Placebo - Test Cognitive tasks 4 similar visits (day 0, day 3, day 6, day 9): Administration of Placebo No stress exposure Placebo - Test Anxiety scale 4 similar visits (day 0, day 3, day 6, day 9): Administration of Placebo No stress exposure Placebo - Test Electromyography (EMG) 4 similar visits (day 0, day 3, day 6, day 9): Administration of Placebo No stress exposure Placebo - Test Electroencephalography (EEG) 4 similar visits (day 0, day 3, day 6, day 9): Administration of Placebo No stress exposure Placebo - Stress Blood collection 4 similar visits (day 0, day 3, day 6, day 9): Administration of Placebo Stress exposure Placebo - Test Blood collection 4 similar visits (day 0, day 3, day 6, day 9): Administration of Placebo No stress exposure Placebo - Test Placebo 4 similar visits (day 0, day 3, day 6, day 9): Administration of Placebo No stress exposure Placebo - Stress Placebo 4 similar visits (day 0, day 3, day 6, day 9): Administration of Placebo Stress exposure Placebo - Stress Cognitive tasks 4 similar visits (day 0, day 3, day 6, day 9): Administration of Placebo Stress exposure Placebo - Stress Stress exposure 4 similar visits (day 0, day 3, day 6, day 9): Administration of Placebo Stress exposure Placebo - Stress Anxiety scale 4 similar visits (day 0, day 3, day 6, day 9): Administration of Placebo Stress exposure Placebo - Stress Electromyography (EMG) 4 similar visits (day 0, day 3, day 6, day 9): Administration of Placebo Stress exposure Placebo - Stress Electroencephalography (EEG) 4 similar visits (day 0, day 3, day 6, day 9): Administration of Placebo Stress exposure
- Primary Outcome Measures
Name Time Method Reaction Time At day 9 (9 days after enrollment) Reaction Time at the cognitive tasks
Number of incorrect responses At day 9 Number of incorrect responses at the cognitive tasks
- Secondary Outcome Measures
Name Time Method Error negativity At day 9 Error negativity on motor evoked potentials (measured by EMG)
Correlation coefficient between anxiety level and tyrosinemia At day 9 Correlation coefficient between anxiety level (measured by anxiety scale) and tyrosinemia (measured in blood sample)
Correlation coefficient between anxiety level and plasma tyrosine At day 9 Correlation coefficient between anxiety level (measured by anxiety scale) and plasma tyrosine (measured in blood sample)
Correlation coefficient between cortisolaemia and melatoninaemia At day 9 Correlation coefficient between cortisolaemia and melatoninaemia (measured in blood sample)
Trial Locations
- Locations (1)
Institut de Recherche Biomédicale des Armées
🇫🇷Brétigny-sur-Orge, France